C

Corvus Pharmaceuticals
D

CRVS

3.95500
USD
-0.04
(-0.88%)
مغلق
حجم التداول
12,007
الربح لكل سهم
-0
العائد الربحي
-
P/E
-4
حجم السوق
304,988,385
أصول ذات صلة
A
ALT
-0.14000
(-2.86%)
4.75000 USD
A
AYTU
0.07000
(3.04%)
2.37000 USD
MRNA
MRNA
0.195
(0.64%)
30.480 USD
N
NNVC
-0.00500
(-0.36%)
1.39000 USD
N
NVAX
0.04000
(0.59%)
6.79000 USD
R
RFL
0.01000
(0.53%)
1.91000 USD
V
VCEL
0.130
(0.31%)
41.600 USD
V
VXRT
-0.01110
(-2.53%)
0.42750 USD
المزيد
الأخبار المقالات

العنوان: Corvus Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).